Michael Karavitis Sells 24,940 Shares of Cutera, Inc. (NASDAQ:CUTR) Stock

Cutera, Inc. (NASDAQ:CUTRGet Free Report) EVP Michael Karavitis sold 24,940 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $2.59, for a total transaction of $64,594.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Michael Karavitis also recently made the following trade(s):

  • On Tuesday, May 14th, Michael Karavitis sold 10,848 shares of Cutera stock. The shares were sold at an average price of $2.45, for a total transaction of $26,577.60.

Cutera Stock Down 5.5 %

Shares of NASDAQ CUTR opened at $2.22 on Friday. Cutera, Inc. has a 1-year low of $1.28 and a 1-year high of $21.41. The company has a 50-day moving average of $2.02 and a two-hundred day moving average of $2.47.

Cutera (NASDAQ:CUTRGet Free Report) last issued its quarterly earnings results on Thursday, May 9th. The medical device company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.05). The firm had revenue of $38.79 million during the quarter, compared to analyst estimates of $37.17 million. During the same quarter in the previous year, the business earned ($1.26) earnings per share. As a group, sell-side analysts forecast that Cutera, Inc. will post -5.88 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. William Blair upgraded shares of Cutera from an “underperform” rating to a “market perform” rating in a research report on Friday, March 22nd. StockNews.com upgraded Cutera to a “sell” rating in a report on Friday, May 10th. Finally, Stephens reaffirmed an “overweight” rating and issued a $10.00 price objective on shares of Cutera in a research note on Friday, March 22nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Cutera currently has an average rating of “Hold” and a consensus target price of $12.67.

Check Out Our Latest Stock Report on CUTR

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CUTR. Tower Research Capital LLC TRC lifted its stake in Cutera by 112.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,363 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 4,430 shares during the last quarter. Bayesian Capital Management LP bought a new position in shares of Cutera during the first quarter worth approximately $33,000. Findell Capital Management LLC bought a new position in Cutera during the 4th quarter worth $39,000. SG Americas Securities LLC acquired a new stake in Cutera in the 4th quarter worth about $43,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Cutera in the third quarter valued at approximately $43,000. 90.70% of the stock is currently owned by institutional investors.

Cutera Company Profile

(Get Free Report)

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truFlex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; and excel V+, a vascular and benign pigmented lesion treatment platform.

Recommended Stories

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.